Several other research firms have also issued reports on PETS. Sidoti upgraded shares of Petmed Express from a neutral rating to a buy rating and raised their price target for the stock from $37.00 to $41.00 in a research report on Wednesday, August 19th. ValuEngine raised Petmed Express from a strong sell rating to a sell rating in a research report on Monday, August 3rd.
Shares of Petmed Express stock opened at $30.66 on Wednesday. Petmed Express has a 1 year low of $21.20 and a 1 year high of $42.88. The company’s fifty day simple moving average is $30.82 and its 200-day simple moving average is $33.55. The company has a market cap of $621.48 million, a price-to-earnings ratio of 21.74 and a beta of 0.70.
Petmed Express Company Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Recommended Story: Economic Bubble
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.